For now, the FDA recommends Regeneron’s antibody cocktail instead.
The “total frequency” of the P.1 variant (first identified in Brazil) and variant B.1.351 (first identified in South Africa) now exceeds 10% in Arizona, California, Florida, Indiana, Oregon and Washington state. Illinois and Massachusetts, the P.1 variant has been “continuously elevated at frequencies in excess of 10%,” the announcement said.
Discontinuation was not related to the safety of the cocktail, for which bamlanivimab and etesevimab were administered together. But was quite worried that it would not work with these different species. The pause will not affect distribution in other parts of the country, according to the statement.
The treatment received an emergency license from the Food and Drug Administration in February. Such monoclonal antibody therapy is intended for use in the early stages of COVID-19 infection. For non-hospital patients who are at high risk of serious disease to help prevent patients from leaving the hospital Medication must be given within the day of diagnosis.
For now, the FDA recommends that health care providers in these states use the Regeneron monoclonal cocktail licensed for COVID-19 patients instead.
Clinical trial data so far have shown that Regeneron’s cocktail is slightly more effective than the current main variant than Lilly’s, which in its own laboratory studies showed reduced efficacy in all variants except B.1.1. .7 or UK variant
In a statement to ABC News, Lilly said: “Continually monitor the COVID-19 environment. Evaluate the neutralization of our antibody therapy against mutations and variations. existing and emerging” and will continue to work with all governments and control the body to ensure that their healing goes on “The Right Patient”
Regeneron told ABC News that the cocktail “still looks good” against the concerns. Also included in India and will continue to experiment with new formats as they arise.
Bamlanivimab, Lilly’s monoclonal antibody therapy. Suspended in March initially in three western states and then across the country. Due to concerns over efficacy against variables, the following month Lilly asked the FDA to revoke the treatment’s EUA, a request that was completed on the same day. so that the company can focus more on the preservation of the cocktail
Although Lilly’s antibody treatment is affected by a number of variables, But research so far has shown that the COVID-19 vaccine is effective against these vaccines. All three licensed vaccines have been proven to work effectively against UK strains. which is the most prominent COVID strain in the United States.